Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Lund – page 90

1 359 clinical trials in Lund, Sweden across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Lund at a glance
1 359
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 359 trials in Lund

Open in trial search

Migraine+1

Not recruiting

Study of Eptinezumab as Add-on Treatment for Prevention of Migraine in Adults with Both Migraine and Medication Overuse Headache

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Lung neoplasm malignant

Not recruiting

Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rilvegostomig
  • Sponsor:AstraZeneca AB

Hypercholesterolaemia

Not recruiting

Study on Evolocumab for Reducing Cardiovascular Events in Patients with Acute Myocardial Infarction

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Acute myeloid leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Daiichi Sankyo Inc.

Axial spondyloarthritis+1

Not recruiting

Study of Ixekizumab Treatment Effects on Joint and Bone Inflammation in Patients with Axial Spondyloarthritis and Psoriatic Arthritis Using Advanced Imaging Methods

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ixekizumab
  • Sponsor:Region Hovedstaden

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study on Venetoclax and Dexamethasone for Patients with Relapsed and Refractory Multiple Myeloma with Translocation (11;14)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Lillebaelt Hospital

Neoplasm+2

Not recruiting

Study on the Effects of Selpercatinib in Patients Aged 12 and Older with Advanced Solid Tumors with RET Gene Alteration

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Loxo Oncology Inc.

Amyotrophic lateral sclerosis

Not recruiting

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:PTC Therapeutics Inc.

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Lund

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on chronic coronary syndrome and heart failure prevention, including investigations of hyperemic responses and new combination therapies.

  • Adenosine response studies
  • Heart failure prevention trials
  • Lipoprotein management

Advanced cardiovascular research exploring novel treatment approaches for various cardiac conditions.

02 Oncology Studies

Comprehensive research in multiple cancer types, including melanoma, leukemia, and colorectal cancer, testing innovative therapeutic approaches.

  • Immunotherapy trials
  • Blood cancer treatments
  • Targeted therapy studies

Focus on developing more effective and personalized cancer treatments.

03 Mental Health & Neurology

Groundbreaking research in mental health conditions, including studies of anorexia nervosa and major depressive disorder.

  • Psychedelic therapy research
  • Depression treatment studies
  • Innovative therapeutic approaches

Exploring novel treatment modalities for complex psychiatric conditions.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.